title: RSR13, a synthetic allosteric modifier of hemoglobin, as an adjunct to radiotherapy: preliminary studies with EMT6 cells and tumors and normal tissues in mice.
abstract: RSR13, 2[4-[[(3,5dimethylanilino)carbonyl]methyl]phenoxy]-2-methylpropion ic acid, a synthetic allosteric modifier of hemoglobin, reduces the affinity of hemoglobin for oxygen. The experiments reported here examined the effect of treatment with RSR13, combined with oxygen breathing, on the radiation response of EMT6 mammary tumors in BALB/c mice and of two normal tissues. RSR13 plus oxygen breathing increased the response of EMT6 tumors to irradiation. RSR13 had no discernible effects on tumors rendered maximally hypoxic by nitrogen asphyxiation, no discernible cytotoxic effects in EMT6 tumors, and no effect on the viability or radiation response of EMT6 cells in vitro under either aerobic or hypoxic conditions. The effects of RSR13 therefore reflect changes in tumor oxygenation, rather than a direct cytotoxic or radiosensitizing effect of the drug. RSR13 plus oxygen reduced the hypoxic fraction to 9% from the value of 24% found in both air-breathing and oxygen-breathing mice. Treatment with RSR13 plus oxygen did not alter the radiation response of the bone marrow progenitor cells (CFU-S) or acute radiation reactions in the skin. The improvement in tumor radiation response produced by treatment with RSR13 plus oxygen, combined with the absence of enhanced radiation reactions in the normal tissues, support further testing of RSR13 as an adjunct to radiotherapy.
authors.affiliation: Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut 06520-8040, USA. sara.rockwell@yale.edu
authors.forename: S
authors.initials: S
authors.lastname: Rockwell
authors.forename: M
authors.initials: M
authors.lastname: Kelley
mesh_terms: D000814:Aniline Compounds / Q000494:pharmacology*; D000818:Animals; D000986:Antisickling Agents / Q000494:pharmacology*; D001854:Bone Marrow Cells / Q000187:drug effects / Q000528:radiation effects; D017024:Chemotherapy, Adjuvant; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006454:Hemoglobins / Q000187:drug effects* / Q000528:radiation effects; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000532:radiotherapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D011422:Propionates / Q000494:pharmacology*; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology*; D012867:Skin / Q000187:drug effects / Q000528:radiation effects; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000528:radiation effects
chemical_list: D000814:Aniline Compounds; D000986:Antisickling Agents; D006454:Hemoglobins; D011422:Propionates; D011838:Radiation-Sensitizing Agents; C067396:efaproxiral